Results 11 to 20 of about 4,104 (188)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis [PDF]

Frontiers in Endocrinology, 2022
Introduction Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD).
Alessandro Mondin, Renzo Manara, Giacomo Voltan, Irene Tizianel, Luca Denaro, Marco Ferrari, Mattia Barbot, Carla Scaroni, Filippo Ceccato   +8 more
openalex   +2 more sources

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature

Clinical Case Reports, 2022
Insulinomas are rare neuroendocrine pancreatic tumors that can be associated with severe episodes of hypoglycemia, leading to significant morbidity and mortality.
Hasan Husni, Sara A. Khan, Buraq Alghaieb, Mohammed S. Abusamaan, Thomas W. Donner, Amir H. Hamrahian   +5 more
doaj   +2 more sources

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

Frontiers in Endocrinology
IntroductionPasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing’s disease (CD). Hyperglycemia during treatment can occur because of the drug’s mechanism of action, although treatment discontinuation is rarely ...
Ulla Feldt-Rasmussen, Ulla Feldt-Rasmussen, Marek Bolanowski, Shao-Ling Zhang, Yerong Yu, Przemysław Witek, Pramila Kalra, Noppadol Kietsiriroje, Andrea Piacentini, Alberto M. Pedroncelli, Susan L. Samson   +10 more
doaj   +2 more sources

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Drug Design, Development and Therapy, 2015
Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar ...
Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K   +18 more
doaj   +3 more sources

Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. [PDF]

Rev Endocr Metab Disord
Pasireotide long-acting release (PAS-LAR) is a second-generation somatostatin receptor ligand (SRL) approved for acromegaly treatment. This meta-analysis aimed to evaluate the real-world effectiveness and safety of PAS-LAR in patients with acromegaly ...
Biagetti B, Araujo-Castro M, Tebe C, Marazuela M, Puig-Domingo M.   +4 more
europepmc   +2 more sources

Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide

Medicina
Background and Objectives: High-grade malignant neuroendocrine tumors (G3 NETs) and neuroendocrine carcinomas (NECs) are characterized by rapid proliferation, high metastatic capacity, and strong expression of somatostatin receptors (SSTRs).
Kevin Doello, Maria Angeles Chico, Francisco Quiñonero, Raúl Ortiz, Jose Prados, Cristina Mesas, Consolación Melguizo   +6 more
doaj   +2 more sources

8594 Pasireotide and Pasireotide Combined Treatment in Aggressive, Giant Pituitary Neuroendocrine Tumours [PDF]

J Endocr Soc
Disclosure: K. Ciszek: None. A. Bogusławska: None. M. Komisarz-Calik: None. J. Kunicki: None. A. Hubalewska-Dydejczyk: None. A. Gilis-Januszewska: None.
K. Ciszek, A. Bogusławska, M. Komisarz-Calik, J. Kunicki, A. Hubalewska-Dydejczyk, A. Gilis-Januszewska   +5 more
europepmc   +2 more sources

Pasireotide after Surgery for Persistent Cushing’s Disease [PDF]

Modern Medicine, 2019
Introduction: Cushing’s disease (CD) is characterized by multiple complications, particularly due to the condition itself, but also as a result of curative treatment. Nowadays, transsphenoidal surgery is considered the first-line therapy.
Dan Nicolae PADURARU, Carla SCANTEIE, Alexandra BOLOCAN, Octavian ANDRONIC, Andra MORAR, Cristina GHERVAN, Raluca CIUNT, Bogdan SOCEA, Ovidiu BRATU, Laura Maria DRAGOMIR, Mara CARSOTE, Ana VALEA   +11 more
doaj   +2 more sources

Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. [PDF]

JCEM Case Rep
Acromegaly is a chronic hormonal disorder caused by excessive GH secretion. In addition to physiological symptoms, it is often accompanied by debilitating headaches.
Dabbous Z, Rohani Z, Abdalrubb AK, Alkailani Y, Pivonello R, Elhadd T.   +5 more
europepmc   +2 more sources

Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar [PDF]

Case Reports in Endocrinology, Volume 2025, Issue 1, 2025.
Background Acromegaly, a rare endocrine disorder characterised by excess growth hormone (GH) and insulin‐like growth factor 1 (IGF‐1), is often due to GH‐secreting pituitary adenomas. Pasireotide, a second‐generation somatostatin receptor ligand (SRL), binds to multiple somatostatin receptors (SSTRs) and offers a promising alternative for patients ...
Tarik Elhadd, Zeinab Dabbous, Elabbass A. Abdelmahmuod, Zaina Rohani, Yaman Al Kailani   +4 more
openalex   +2 more sources